Objective: To investigate the current status of institutional review board construction in blood collection and supply institutions in China, and to provide evidence for standardized management of transfusion medicine ethics. Methods: A questionnaire survey was conducted to assess the development of institutional review boards in blood collection and supply institutions in 31 provinces, municipalities and autonomous regions across the country, excluding hong kong, macao and taiwan. Data were statistically analyzed using the chi-square test and Mann-Whitney U test. Results: Among 83 blood collection and supply institutions, the establishment rate of institutional review boards was 66.27% (55/83), with a higher rate in blood centers than in central blood stations. Of the 55 ethics review committees, 83.64% (46/55) uploaded information and completed registration in the National Medical Research Registration and Filing Information System. The registration rate was higher in blood centers than in central blood stations. On average, each institutional review board conducted 3 initial reviews and approved 2 research projects. The number of initial review items and the number of approved research projects were higher in blood centers than in central blood stations. Common problems in both blood centers and central blood stations included the appointment of the main leader as the director or deputy director, insufficient allocation of ethics professionals, and the general absence of an ethical review system for emergencies. Most committees lacked independent venues, and continuous training coverage was incomplete. Meanwhile, blood collection and supply institutions generally showed high level of ethical recognition of existing blood donation incentive measures. Conclusion: Progress has been made in the construction of transfusion medicine ethics in China; however, shortcomings remain in independence, professional composition of committee members, continuous training, and emergency response systems, requiring targeted improvements.

Objective To investigate the therapeutic efficacy of HLA-genotype matched platelet transfusion using a platelet donor database for severe platelet transfusion refractoriness (PTR) caused by HLA antigen-antibody incompatibility. Methods Using real-time quantitative PCR (qPCR) to identify he patient's HLA class I genotype, followed by searching the platelet donor database for matching donors, and selecting highly compatible donors for transfusion. Platelets with higher compatibility levels were prioritized for transfusion recommendations. Results Among the 19 patients studied, 7 patients identified donors with B2U or higher compatibility, 6 patients identified donors with BX or higher compatibility, and 6 patients did not find a suitable donor. The transfusion efficacy was evaluated by calculating the corrected count increment (CCI) 24 hours post-transfusion, and all transfusions were effective. Conclusion The optimal strategy to prevent and treat patients with severe platelet transfusion refractoriness is to ensure patients receive platelet transfusions that are matched to their HLA genes, and this approach significantly enhances transfusion efficacy.
Humans ; Platelet Transfusion/adverse effects* ; HLA Antigens/immunology* ; Male ; Middle Aged ; Female ; Adult ; Blood Platelets/immunology* ; Aged ; Genotype

Objective To identify the sequence variation of human leukocyte antigen(HLA)novel allele A11:193 and to simulate the three-dimensional structure of the protein molecule.Methods A sample with abnormal allele results was found by PCR-SBT sequencing and identified by single allele specific sequencing.The 3D structure of the encoded protein was analyzed by Swiss-Model.Results Compared with HLA-A*11:01:01,which has the highest homology,exon 4 nt 662 of this sample has a base substitution of A→G,and its corresponding codon 197 is changed from CAT to CGT,which is changed from histidine(His)to arginine(Arg).Conclusion A new allele of HLA-A was confirmed.The allele sequence was named HLA-A11:193 by the WHO HLA Factor Nomenclature Committee and the three-dimensional structure of the protein molecule encoded by HLA-A11:193 was simulated.There was no significant difference in the three-dimensional structure of the encoded protein between it and HLA-A*11:01:01.

Objective To identify the sequence variation of human leukocyte antigen(HLA)novel allele A11:193 and to simulate the three-dimensional structure of the protein molecule.Methods A sample with abnormal allele results was found by PCR-SBT sequencing and identified by single allele specific sequencing.The 3D structure of the encoded protein was analyzed by Swiss-Model.Results Compared with HLA-A*11:01:01,which has the highest homology,exon 4 nt 662 of this sample has a base substitution of A→G,and its corresponding codon 197 is changed from CAT to CGT,which is changed from histidine(His)to arginine(Arg).Conclusion A new allele of HLA-A was confirmed.The allele sequence was named HLA-A11:193 by the WHO HLA Factor Nomenclature Committee and the three-dimensional structure of the protein molecule encoded by HLA-A11:193 was simulated.There was no significant difference in the three-dimensional structure of the encoded protein between it and HLA-A*11:01:01.

OBJECTIVETo report on a novel HLA-A allele, A*29:49, identified in a Chinese Han population by sequence based typing (SBT).

METHODSA donor from China Marrow Donor Programme (CMDP) was typed with a bi-allelic PCR-SBT kit, and no full matched result was obtained for the HLA-A locus. The novel HLA allele was verified with an allele-specific amplification SBT kit.

RESULTSA novel HLA-A allele was identified, which has differed by one nucleotide from the closest matched allele, HLA-A*29:01:01:01, at position 368(A→T), codon 99 (TAT→TTT), resulting in an amino acid substitution (Y→F). Another allele was verified as A*02:06:01.

CONCLUSIONA novel HLA-A allele was identified and officially named as HLA-A*29:49 by the WHO Nomenclature Committee for Factors of the HLA System.

Alleles ; Amino Acid Substitution ; genetics ; Base Sequence ; China ; HLA-A Antigens ; genetics ; Humans ; Sequence Analysis, DNA ; methods